The FDA has accepted for Priority Review the New Drug Application for TransCon CNP (navepegritide) for the treatment of children with achondroplasia.

For TransCon CNP treatment-naïve children, mean annualized growth velocity (AGV) was 9.14 cm/year, representing an increase from baseline at Week 26 of 4.23 cm/year, with an improvement in mean ACH ...

Incyte trades -8.61% away from its average analyst target price of $73.88 per share. The 23 analysts following the stock have set target prices ranging from $52.0 to $96.0, and on average have given ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

4 About Roche’s medicines for human epidermal growth factor receptor 2 (HER2)-positive breast cancer Roche has been leading research into the HER2 pathway for over 30 years and is committed to ...